CJC-1295 No-DAC vs MK-677: Pulsatile vs Continuous GH Stimulation

CJC-1295 no-DAC and MK-677 (ibutamoren) both elevate GH and IGF-1 but through completely different mechanisms and with dramatically different metabolic consequences.

CJC-1295 no-DAC is a short-acting GHRH analog. Its plasma half-life is approximately 30 minutes. It binds the GHRH receptor on pituitary somatotrophs, priming and amplifying GH release in a pulsatile pattern that mimics normal physiology. It is almost always co-administered with ipamorelin (a selective GHRP) to produce a larger, more complete GH pulse. The result is 1 to 3 discrete GH pulses per day, each lasting 2 to 3 hours, with full insulin sensitivity recovery in the intervals.

MK-677 is an oral, non-peptide GHS-R1a agonist with a plasma half-life of approximately 24 hours. A single daily oral dose maintains GH stimulation continuously across the 24-hour period, producing sustained GH and IGF-1 elevation without the physiological pulse pattern. Nass et al. (2008, PMID 18981485) conducted the definitive 2-year randomised controlled trial of MK-677 at 25 mg/day in 65 healthy older adults, documenting a 50 to 100% IGF-1 increase, meaningful muscle mass gain, but also a 0.3 mmol/L rise in fasting glucose, a 0.2% HbA1c increase, and 37% of subjects shifting toward pre-diabetic glucose levels.

The fundamental trade-off is convenience and IGF-1 ceiling (MK-677) versus metabolic safety and physiological pulse pattern (CJC-1295 no-DAC plus ipamorelin).

Mechanism of GH stimulation:

• CJC-1295 no-DAC: GHRH receptor agonist; activates somatotrophs via cAMP-PKA; always used with ipamorelin (GHS-R1a trigger) for a synergistic pulse
• MK-677: GHS-R1a agonist (same receptor as ghrelin); acts at pituitary, hypothalamus, and peripherally; produces continuous GH stimulation

GH release pattern:

• CJC-1295 no-DAC plus ipamorelin: discrete 2 to 3 hour GH pulses, 1 to 3 per day; GH returns to baseline between pulses
• MK-677: near-continuous GH stimulation across 24 hours due to the long half-life; no meaningful inter-dose recovery window

IGF-1 elevation:

• CJC-1295 no-DAC plus ipamorelin: 20 to 60% above baseline with standard protocols; depends on injection frequency and dose
• MK-677 (25 mg/day): 50 to 100% above baseline in the 2-year RCT (Nass et al., 2008); higher absolute ceiling

Glucose and insulin resistance:

• CJC-1295 no-DAC plus ipamorelin: fasting glucose and HOMA-IR not expected to change meaningfully; tesamorelin (related GHRH analog) showed no glucose change in 806 patients over 52 weeks (Falutz 2010)
• MK-677 (25 mg/day): fasting glucose rose 0.3 mmol/L (Nass 2008); HbA1c rose 0.2%; 37% of subjects shifted toward pre-diabetic glucose range; fasting insulin rose with compensatory hyperinsulinemia

Cortisol and prolactin effects:

• CJC-1295 no-DAC plus ipamorelin: no cortisol or prolactin elevation; both components are hormonally selective
• MK-677: mildly elevates cortisol in some studies through ghrelin receptor activation; less than GHRP-6 but not zero; some users report prolactin changes

Appetite:

• CJC-1295 no-DAC plus ipamorelin: minimal appetite stimulation; ipamorelin's pituitary selectivity avoids the hypothalamic ghrelin appetite signal
• MK-677: significant appetite stimulation through hypothalamic GHS-R1a activation; a feature during bulk phases, a drawback during cuts

Route and convenience:

• CJC-1295 no-DAC plus ipamorelin: subcutaneous injections, 1 to 3 times daily; refrigeration required; requires reconstitution
• MK-677: oral capsule or tablet, once daily at any time; no refrigeration; no reconstitution; no injection burden

Cost (estimated grey market, May 2026):

• CJC-1295 no-DAC plus ipamorelin: approximately USD $80 to $150 per month for vials plus bacteriostatic water and syringes
• MK-677: approximately USD $30 to $80 per month for oral capsules; significantly cheaper in equivalent IGF-1 elevation terms

Long-term safety data:

• CJC-1295 no-DAC plus ipamorelin: no long-term RCT; tesamorelin (52 weeks, 806 patients) is the closest proxy for the GHRH component
• MK-677: 2-year RCT in humans (Nass et al., 2008) with documented safety profile including the glucose signal

Choose CJC-1295 no-DAC plus ipamorelin if:

• You are metabolically sensitive, have borderline fasting glucose, insulin resistance, or family history of type 2 diabetes
• You are in a cutting phase where appetite stimulation is unwanted and glucose management is a priority
• You already have good GH peptide injection discipline and want the cleanest hormonal profile
• You are stacking with compounds that already affect insulin sensitivity (high-dose testosterone, GH, or AAS)
• You want cortisol-neutral and prolactin-neutral GH elevation without managing additional hormonal side effects
• Cost is less important than metabolic profile

Choose MK-677 if:

• You are in a bulk phase where appetite stimulation and anabolism from higher IGF-1 are welcomed
• You cannot or will not inject; oral convenience is the decisive factor
• You are metabolically healthy with no insulin resistance, no pre-diabetes, and low cardiovascular risk
• You want maximum IGF-1 ceiling and are willing to monitor and manage the metabolic consequences
• Cost is a primary consideration; MK-677 is substantially cheaper per unit IGF-1 elevation

Sequencing approach for advanced users:

• Bulk phase: MK-677 for appetite support and high IGF-1; monitor glucose quarterly
• Cut phase: switch to ipamorelin plus CJC-1295 no-DAC for metabolic safety and hunger control
• Year-round: CJC-1295 no-DAC plus ipamorelin as the sustainable, metabolically conservative baseline

For users over 40 or with metabolic risk factors: CJC-1295 no-DAC plus ipamorelin is strongly preferred. The 2-year MK-677 data showing glucose deterioration is particularly relevant for this demographic where pre-diabetes risk is already elevated.